Dihydroagarofuran type sesquiterpenoids, extract containing dihydroagarofuran type sesquiterpenoids and application of dihydroagarofuran type sesquiterpenoids

By extracting petroleum ether and sesquiterpenes of Kunming Mountain Begonia fruits, dihydrogen agarwood furanyl sesquiterpenes were discovered, which solved the problem of unutilized fruits in the treatment of inflammation and realized the application of anti-inflammatory drugs for the fruits.

CN119707883AActive Publication Date: 2025-03-28KUNMING INST OF BOTANY CHINESE ACAD OF SCI
3 Cites 0 Cited by

Patent Information

Application Number
CN202411893887.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-20
Publication Date
2025-03-28
Estimated Expiration
2044-12-20

AI Technical Summary

Technical Problem

The prior art has not yet used Kunming Mountain Begonia fruit as a medical use for the treatment of inflammation, and there are no relevant reports on the chemical composition and physiological activities of the fruit site.

Method used

By extracting petroleum ether into the Kunming Mountain Begonia fruit, toxicity was reduced and the chemical composition was separated by the system, it was found that it was rich in dihydrogen agarwood furan-type sesquiterpenes. These compounds were prepared by extraction and showed excellent anti-inflammatory activity.

Benefits of technology

It has realized the medical use of Kunming Mountain Begonia fruit in the treatment of inflammation, provided new pharmacological active substances, and solved the problem of material basis in the fruit part.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The embodiment of the invention discloses dihydroagarofuran type sesquiterpenoids, an extract containing the dihydroagarofuran type sesquiterpenoids and application of the dihydroagarofuran type sesquiterpenoids. The method comprises the following steps: extracting tripterygium hypoglaucum fruits with petroleum ether and ethyl acetate, and sequentially carrying out silica gel column chromatography, gel column chromatography, C-18 reversed-phase column chromatography, high performance liquid chromatography (HPLC) and other separation methods to obtain a series of dihydroagarofuran type sesquiterpenoids. In-vitro tests verify that the dihydroagarofuran type sesquiterpenoids provided by the invention have no obvious toxicity, and the extract and monomeric compounds containing the dihydroagarofuran type sesquiterpenoids have a better anti-skin inflammation effect.
Need to check novelty before this filing date? Find Prior Art